PubRank

J S Thomsen

Author PubWeight™ 30.58‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The orphan nuclear receptor SHP inhibits agonist-dependent transcriptional activity of estrogen receptors ERalpha and ERbeta. J Biol Chem 1999 1.46
2 The orphan nuclear receptor SHP utilizes conserved LXXLL-related motifs for interactions with ligand-activated estrogen receptors. Mol Cell Biol 2000 1.26
3 Lumbar vertebral body compressive strength evaluated by dual-energy X-ray absorptiometry, quantitative computed tomography, and ashing. Bone 1999 1.22
4 DAX-1 functions as an LXXLL-containing corepressor for activated estrogen receptors. J Biol Chem 2000 1.20
5 Competition between thyroid hormone receptor-associated protein (TRAP) 220 and transcriptional intermediary factor (TIF) 2 for binding to nuclear receptors. Implications for the recruitment of TRAP and p160 coactivator complexes. J Biol Chem 1999 1.16
6 Age-related changes in the biochemical properties of human cancellous bone collagen: relationship to bone strength. Calcif Tissue Int 1999 1.12
7 Age- and gender-related differences in vertebral bone mass, density, and strength. J Bone Miner Res 1999 0.97
8 The positive effects of zinc on skeletal strength in growing rats. Bone 2001 0.96
9 Trabecular bone structure and strength - remodelling and repair. J Musculoskelet Neuronal Interact 2000 0.96
10 Effects of exercise and disuse on bone remodeling, bone mass, and biomechanical competence in spontaneously diabetic female rats. Bone 2000 0.93
11 PTH and interactions with bisphosphonates. J Musculoskelet Neuronal Interact 2000 0.92
12 Nondestructive determination of iliac crest cancellous bone strength by pQCT. Bone 1997 0.90
13 Comparative properties of the nuclear aryl hydrocarbon (Ah) receptor complex from several human cell lines. Eur J Pharmacol 1995 0.90
14 The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment. Bone 2006 0.88
15 Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats. Bone 1995 0.86
16 Additive effect of voluntary exercise and growth hormone treatment on bone strength assessed at four different skeletal sites in an aged rat model. Bone 1999 0.86
17 Analysis of the effects of growth hormone, voluntary exercise, and food restriction on diaphyseal bone in female F344 rats. Bone 1999 0.84
18 A comparison of the effects of two anabolic agents (fluoride and PTH) on ash density and bone strength assessed in an osteopenic rat model. Bone 1997 0.83
19 Vertebral bone density evaluated by dual-energy X-ray absorptiometry and quantitative computed tomography in vitro. Bone 1998 0.83
20 Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats. Endocrinology 2002 0.82
21 Growth hormone mitigates loss of periosteal bone formation and muscle mass in disuse osteopenic rats. J Musculoskelet Neuronal Interact 2014 0.81
22 Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats. Bone 2000 0.81
23 Long-term excessive magnesium supplementation is deleterious whereas suboptimal supply is beneficial for bones in rats. Magnes Res 2000 0.81
24 Parathyroid hormone and growth hormone have additive or synergetic effect when used as intervention treatment in ovariectomized rats with established osteopenia. Bone 2000 0.80
25 Decreased trabecular bone biomechanical competence, apparent density, IGF-II and IGFBP-5 content in acromegaly. Eur J Clin Invest 2002 0.80
26 Parathyroid hormone increases bone formation and improves mineral balance in vitamin D-deficient female rats. Endocrinology 1997 0.80
27 No loss of biomechanical effects after withdrawal of short-term PTH treatment in an aged, osteopenic, ovariectomized rat model. Bone 1997 0.79
28 Growth hormone increases vertebral and femoral bone strength in osteopenic, ovariectomized, aged rats in a dose-dependent and site-specific manner. Bone 1998 0.79
29 Three-dimensional microstructural properties of regenerated mineralizing tissue after PTH (1-34) treatment in a rabbit tibial lengthening model. J Musculoskelet Neuronal Interact 2009 0.79
30 Sequential treatment with basic fibroblast growth factor and parathyroid hormone restores lost cancellous bone mass and strength in the proximal tibia of aged ovariectomized rats. J Bone Miner Res 2001 0.79
31 Skeletal growth and long-term bone turnover after enterocystoplasty in a chronic rat model. BJU Int 2003 0.78
32 A histomorphometric and scanning electron microscopy study of human condylar cartilage and bone tissue changes in relation to age. Clin Orthod Res 1999 0.78
33 Autometallographic tracing of zinc ions in growing bone. J Musculoskelet Neuronal Interact 2004 0.77
34 Influence of a low calcium and phosphorus diet on the anabolic effect of human parathyroid hormone (1-38) in female rats. Bone 2001 0.77
35 Effect of transient expression of the oestrogen receptor on constitutive and inducible CYP1A1 in Hs578T human breast cancer cells. Br J Cancer 1996 0.77
36 Alterations in gene expression precede sarcopenia and osteopenia in botulinum toxin immobilized mice. J Musculoskelet Neuronal Interact 2016 0.75
37 Pantoprazole, a proton pump inhibitor, does not prevent botulinum toxin induced disuse osteopenia in mice. J Musculoskelet Neuronal Interact 2017 0.75
38 Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 1999 0.75
39 Application of design-based stereology for estimation of absolute volume and surface area of the articular and calcified cartilage compartments of undecalcified human femoral heads. J Microsc 2013 0.75
40 The effect of enterocystoplasty on bone strength assessed at four different skeletal sites in a rat model. Bone 2003 0.75